Compare Novavax Inc (NVAX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs VF Corp — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while VF Corp trades at $15 (market cap $5.71B). The key difference: VF Corp is far larger — about 3.1× Novavax Inc's market cap, and VF Corp pays a 2.48% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and VF Corp for 65 Days on average.
| NVAX | VFC | |
|---|---|---|
Market Cap | $1.82B | $5.71B |
Volume | 6,198,505 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.75 | $21.55 |
52-Week Low | $6.22 | $12.62 |
Typical Hold Time | 59 Days | 65 Days |
Enterprise Value | $1.39B | $10.00B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
VFC trades at $14.53, up 1.04% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $11.8B in 2022 to $9.5B in 2025 and negative net income of -$189.72M, though 2026 projects a return to profitability. Analyst consensus is Hold with a $18.33 price target, representing 26% upside. Recent news highlights Vans brand weakness offset by Outdoor segment strength.
The outlook remains cautious with execution risk around the Vans turnaround being the key challenge. The discounted valuation (P/S 0.61) offers potential upside if management can stabilize operations, but persistent revenue declines and recent dividend cut signal ongoing headwinds. Risk-reward appears balanced near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
